Preprint HERV Dysregulation in a Case of Myalgic Encephalomyelitis and Multiple Sclerosis Responsive to Rituximab, 2025, Martín-Martínez et al

HERV Dysregulation in a Case of Myalgic Encephalomyelitis and Multiple Sclerosis Responsive to Rituximab

Eva Martín-Martínez, Sara Gil-Perotin, Karen Giménez-Orenga, Lucas Barea-Moya, Elisa Oltra

[Line breaks added]

Abstract
This article summarizes the case of 30-year-old male diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and its longitudinal follow up that provided a secondary diagnosis of Multiple Sclerosis (MS) eight years after. The most impactful result being his response to rituximab treatment after the systematic failure of prior treatments.

Although the expression of endogenous retroviral proteins has been associated with autoimmunity, the patient did not show increased expression of the toxic protein HERV (human endogenous retrovirus)-W ENV, a target of the ongoing clinical trials with temelimab in MS and long COVID-19 cases. However, genome-wide HERV transcriptome analysis by high density microarrays clearly revealed a distinct profile in patients blood supportive of an altered immune system.

Limitations of the study include MRI imaging follow up to monitor lesion progression and reassessment of HERV profiles after rituximab. As an overall, the coincidence of HERV alterations and the impactful response to rituximab presents the possibility of additional, more specific, therapeutic targets encoded by other HERV elements yet to be discovered.

Link | PDF (Preprint: Preprints.org) [Open Access]

 

Interesting to see this small group in Valencia has done a few papers on ME. They have a GP working with them on the clinical side, Dr. Eva Martin Martinez..
https://sindromedefatigacronicapuntodeencuentro.wordpress.com/inicio/

They also did this paper:
https://www.s4me.info/threads/over-...me-cfs-2024-giménez-orenga-oltra-et-al.39619/